Hygeia journal for Drugs and Medicines

Abstract

Amelioration of CNS Toxicities of L-Dopa in Experimental Models of Parkinson’s Disease by Concurrent Treatment with Tinospora cordifolia
Hygeia J. D. Med. Vol.2 (1) 2010, 28-38


Type of Article
Research Article

Authors
Shanish Antony A*, Partha DebRoy , Vadivelan R , Jaysankar K ,
Vikram M , Nandini S , Sundeep M , Elango K , Suresh B . 


Affiliation
Department of Pharmacology and Toxicology, J. S. S. College of Pharmacy, Ootacamund, Tamil nadu , India . 
 

Received Date
22/02/2009

Publication Date
05/09/2009

Abstract

Parkinson’s disease is the second most common neurodegenerative disease, primarily affecting people of ages over 45-55 years, although young adults and even children can also be affected. The gold standard drug for the treatment of Parkinson’s disease is L-DOPA, but various studies have proved that the treatment with L-DOPA leads to the death of surviving dopaminergic neurons in the CNS1. Hence we have approached to counteract the toxicities of L-DOPA therapy by co-administration of Tinospora cordifolia crude powder. On the zero day each animals were given with an intraperitoneal (ip) injection of 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) (20mg/kg) and after 48 hours the animals were treated with L-DOPA or L-DOPA plus Tinospora cordifolia crude powder upto 30 days. At the end of the study period we were evaluated the level of anxiety, grip strength and mitochondrial complex-I activity. The results revealed that the co-administration of Tinospora cordifolia crude powder protected the dopaminergic neurons when compared with Sham operated control group. In conclusion, we would like to state that the treatment with Tinospora cordifolia crude powder could reduce the toxicities of L-DOPA therapy for Parkinson’s disease.


Keywords: Parkinson’s disease, CNS toxicities, L-DOPA, Tinospora cordifolia, MPTP

Article Outline
1. Introduction
2. Materials and methods
3. Acute toxicity study of TCCP
4. Pharmacological Evaluation 
4.1. Anti-anxiety activity
4.2. Muscle grip strength study
5. Molecular pharmacological evaluation
5.1. Isolation of mitochondria from rat mid brain
5.2. Estimation of Complex-I activity
6. Statistical analysis
7. Results
7.1. Effect of L-DOPA and L-DOPA plus TCCP on anxiety behavior
7.2. Effect of L-DOPA and L-DOPA plus TCCP on muscle grip strength
7.3. Effect of L-DOPA and L-DOPA plus TCCP on Complex-I activity
8. Discussion
9. Conclusion

Graphical Outline: (HPTLC chromatogram of standard tinosporaside)



For Contact: +91 934321803
shanishantony@yahoo.com
© 2010 Hygeia journal for drugs and medicines. ,All rights reserved. 0975 6221, 2229 3590

Citations available at:








Videos

  • watch Video
    Collagen Mimetic Peptides
  • watch Video
    Immunotherapy to fight cancer
  • watch Video
    Food Safety Emergency Prevention
  • watch Video
    Tiny worm-like robot could deliver medicine inside body
  • watch Video
    This smart pill could crawl through your body to deliver its medicine
  • watch Video
    Introduction To Nanorobotics: A conversation
  • watch Video
    How AI is accelerating drug discovery - Nature's Building Blocks | BBC Story Works
  • watch Video
    How are Pharmaceutical Companies Using Artificial Intelligence?
  • watch Video
    The links between telomerase and aging